Goldman Sachs led a $93.5m Series A round in Newleos Therapeutics.

Goldman Sachs, an alternative investment platform of Goldman Sachs Asset Management, led a $93.5m Series A round in Newleos Therapeutics, a clinical-stage neuroscience company developing oral small molecules for neuropsychiatric disorders, with participation from Novo Holdings, Longwood Fund, DCVC Bio, and Arkin Bio. “Anxiety and substance use disorders represent some of the most prevalent neuropsychiatric indications with high unmet need, representing over 25 percent of mental illnesses in US adults and impacting over 60 million individuals. With a seasoned, founding team that has extensive company creation and CNS drug development experience, Newleos will use this capital to conduct proof-of-concept clinical trials across our programs,” David Donabedian, Newleos CEO and Longwood Fund Executive Partner.